- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00630682
A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence (1D)
May 30, 2013 updated by: Gantt Galloway, PharmD, California Pacific Medical Center Research Institute
The purpose of this study is to assess the safety and effectiveness dextroamphetamine to help methamphetamine users quit or cut down on their use.
The study lasts for 9 weeks.
Eligible participants will attend research visits twice per week, and will receive individual counseling sessions once per week for all 9 weeks.
50% of the participants will receive the active medication while the other 50% will receive the placebo (sugar pill).
Neither the participant or the study team will know if the participant is receiving the placebo or active drug.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- CPMC-St. Luke's Campus-Addiction Pharmacology Research Laboratory
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 46 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-50 yrs. old
Exclusion Criteria:
pregnant or lactating females
- Contact site for additional information
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Dextroamphetamine
Active drug
|
1 week placebo and 8 weeks 60mg d-AMP QD.
|
|
Placebo Comparator: Placebo
Placebo of drug
|
9 weeks of placebo 60mg capsules QD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Subjects treated with dextroamphetamine will have better outcomes than subjects treated with placebo, as indicated by the number of urine samples that do not indicate new use of MA (the primary outcome measure)
Time Frame: Twice per week for 8 weeks
|
Twice per week for 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Gantt Galloway, PharmD, Addiction Pharmacology Research Laboratory
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
March 1, 2009
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
February 28, 2008
First Submitted That Met QC Criteria
March 6, 2008
First Posted (Estimate)
March 7, 2008
Study Record Updates
Last Update Posted (Estimate)
June 3, 2013
Last Update Submitted That Met QC Criteria
May 30, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Compulsive Behavior
- Impulsive Behavior
- Behavior, Addictive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Dextroamphetamine
Other Study ID Numbers
- 25.139
- P50DA018179 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methamphetamine Addiction
-
Adai Technology (Beijing) Co., Ltd.Completed
-
Baylor College of MedicineUniversity of California, Los AngelesCompletedMethamphetamine AddictionUnited States
-
California Pacific Medical Center Research InstituteCompletedMethamphetamine AddictionUnited States
-
Ruijin HospitalUnknownTreatment Methamphetamine AddictionChina
-
Centre hospitalier de l'Université de Montréal...Canadian Institutes of Health Research (CIHR)RecruitingAddiction | Methamphetamine-dependence | Addiction, Substance | Methamphetamine AbuseCanada
-
Centre hospitalier de l'Université de Montréal...Health Canada; Ministere de la Sante et des Services SociauxRecruitingAddiction | Methamphetamine-dependence | Substance Abuse | Methamphetamine Use Disorder | Methamphetamine AbuseCanada
-
Shanghai Mental Health CenterCompleted
-
Shanghai Mental Health CenterActive, not recruiting
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Addiction | Crystal Meth Addiction | Amphetamine AddictionUnited States
-
Ryan M. CarnahanUniversity of Utah; University of New MexicoCompletedMethamphetamine-dependence | Stimulant Dependence | Addiction, DrugUnited States
Clinical Trials on Dextroamphetamine
-
Ironshore Pharmaceuticals and Development, IncCompletedAttention-Deficit Hyperactivity Disorder (ADHD)United States
-
Medical University of ViennaUnknownSchizophrenia | Psychosis | SensitisationAustria
-
The University of Texas Health Science Center,...TerminatedSubstance-Related Disorders | Cocaine-Related Disorders | Attention Deficit Disorder With HyperactivityUnited States
-
ShireTerminated
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine DependenceUnited States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity | Binge-Eating DisorderUnited States
-
Jeffrey NewcornNational Institute on Drug Abuse (NIDA)CompletedConduct Disorder | Substance Abuse | Attention Deficit Disorder With HyperactivityUnited States
-
University of MinnesotaActive, not recruiting
-
University of California, San DiegoCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Eva SzigethyThe Beckwith InstituteTerminated